Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-597-4 | CAS number: 1215841-86-3
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
In vitro studies:
Three in vitro genetic toxicity tests were performed to examine the potential of the substance trans-N1,N1,N4,N4-Tetrakis(2-hydroxyethyl)1,4-cyclohexanedicarboxamide to induce mutations.
In a bacterial mutation test using the Salmonella typhimurium strains TA 1535, TA 1537, TA 98, TA 100 and TA 102, with and without the addition of a metabolising system according to OECD method 471 tested up to a concentration of 5000 µg/plate, the substance caused no mutagenic effect neither in the plate incorporation test nor in the preincubation test each carried out without and with metabolic activation.
Furthermore an in vitro micronucleus test was conducted. Under the present test conditions, tested up to a concentration of 5000 µg /mL medium in the absence and in the presence of metabolic activation the substance revealed no indications of mutagenic properties in the in vitro micronucleus test.
The substance was tested for mutagenic potential in a gene mutation assay in cultured mammalian cells (HPRT test) both in the presence and absence of metabolic activation. Under the present test conditions, tested up to concentrations of 5000 µg/mL in the experiments without and with metabolic activation the substance was negative in the HPRT-V79 mammalian cell mutagenicity test
Short description of key information:
Three in vitro genetic toxicity tests were performed to examine the potential of the substance trans-N1,N1,N4,N4-Tetrakis(2-hydroxyethyl)1,4-cyclohexanedicarboxamide to induce mutations. The substance showed no mutagenic properties in the bacterial mutation test, in the in vitro micronucleus test and in the in vitro mammalian gene mutation test (HPRT test).
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
According to the criteria of EC Directive 67/548/EEC and EC Regulation 1272/2008 and subsequent regulations on classification, labelling and packaging of substances and mixtures and based on the results of the studies trans-N1,N1,N4,N4-Tetrakis(2-hydroxyethyl)1,4-cyclohexanedicarboxamide is not classified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
